Skip to content
Skip to navigation menu


Prof Michael A O Lewis 

Michael O.A. Lewis
Position:Dean of School of Dentistry, Professor of Oral Medicine

Telephone:+44 (0)29 2074 2470

Mike Lewis is the Dean and Head of the School of Dentistry, Cardiff University. He also holds the position of Divisional Director of the Dental Division of the Cardiff and Vale University Health Board.

As Dean, he has overall responsibility for all matters related to the learning, teaching and training of the dental team and provides a strategic lead in these matters both for the University and within Wales. He also holds similar responsibilities for the international research profile of the school. As elsewhere in the university the teaching is research led and the school has a world class reputation in a number of areas.

As a Divisional Director, he has overall responsibility for the provision of clinical care to approximately 250,000 patients per year within the Dental Division of the Cardiff and Vale University Health Board. This includes the clinical facilities and support to train dental undergraduates, professionals complementary to dentistry and speciality postgraduates as well as the provision of facilities for the training of the whole dental team.

The strategic leadership and management of the School and the Cardiff and Vale University Health Board is performed in an innovative seamless manner since the missions of the two organisations are so interrelated and dependant on each other.

Research Theme

Applied Clinical Research & Public Health

Research Group

Microbial Effects on Tissue Function, and Tissue Repair and Remodelling

Research Interests

Antimicrobial agents

Antimicrobial resistance

Acute dental infection


Herpes simplex infections

Infection control


Selected Projects

A preference trial to investigate patient perception with a commercially available wound care product on the lesion caused by recurrent herpes labialis.

A multicentre double blind active controlled parallel study comparing the efficacy and safety of aciclovir 5% and lignocaine 2% to aciclovir 5% alone in subjects with herpes labialis

A randomised, double blind, single dose, one day early administration, multicentre study comparing the efficacy and safety of acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching placebo in the treatment of herpes labialis.

UK national susceptibility survey of dental pathogens.

Related Links

Dental Faculty, Royal College of Physicians and Surgeons of Glasgow